Dr. Matthew T. Oliver
Claim this profileWomen and Infants Hospital
Studies Cancer
Studies Ovarian Cancer
7 reported clinical trials
17 drugs studied
Area of expertise
1Cancer
KRAS positive
NRAS positive
HRAS positive
2Ovarian Cancer
KRAS positive
NRAS positive
HRAS positive
Affiliated Hospitals
Clinical Trials Matthew T. Oliver is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Tailored Therapy
for Endometrial Cancer
This phase II trial tests how well tailoring therapy in post-surgery works in patients with low-risk endometrial cancer. The usual approach for patients with low-risk endometrial cancer is treatment with surgery. In this study, tissue that is removed as part of the surgical procedure is analyzed in the pathology laboratory to help guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Recruiting1 award Phase 24 criteria
More about Matthew T. Oliver
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Matthew T. Oliver has experience with
- VMD-928
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- Nivolumab
- Ipilimumab
- Carboplatin
Breakdown of trials Matthew T. Oliver has run
Cancer
Ovarian Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew T. Oliver specialize in?
Matthew T. Oliver focuses on Cancer and Ovarian Cancer. In particular, much of their work with Cancer has involved KRAS positive patients, or patients who are NRAS positive.
Is Matthew T. Oliver currently recruiting for clinical trials?
Yes, Matthew T. Oliver is currently recruiting for 6 clinical trials in Providence Rhode Island. If you're interested in participating, you should apply.
Are there any treatments that Matthew T. Oliver has studied deeply?
Yes, Matthew T. Oliver has studied treatments such as VMD-928, Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide.
What is the best way to schedule an appointment with Matthew T. Oliver?
Apply for one of the trials that Matthew T. Oliver is conducting.
What is the office address of Matthew T. Oliver?
The office of Matthew T. Oliver is located at: Women and Infants Hospital, Providence, Rhode Island 02905 United States. This is the address for their practice at the Women and Infants Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.